Cinacalcet
- PDF / 169,453 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 2 Downloads / 117 Views
1 S
Lack of efficacy: case report In a retrospective study, involving 10 patients who were treated with denosumab for hypercalcaemia secondary to primary hyperparathyroidism (PHPT) from January 2016 to June 2020, a 44-year-old woman was described, who exhibited lack of efficacy during treatment with cinacalcet for hypercalcaemia. The woman (case 3) had been diagnosed with hypercalcaemia secondary to PHPT. She also exhibited PHPT complications including osteoporosis, kidney stones and impaired renal function, and hypercalaemia related complications including cognitive impairment, headaches, dizziness, nausea, vomiting and dehydration. She was hospitalised. At baseline, her serum calcium level was 3.34 mmol/L and eGFR was 44 mL/min/1.73m2. Subsequently, she started receiving treatment with cinacalcet 90mg [route not stated] with concurrent isotonic sodium-chloride [saline]. However, she exhibited lack of effect of cinacalcet. Therefore, she started receiving denosumab [Prolia] injection. On 3rd day of the injection, she achieved normocalcaemia (2.46 mmol/L). Eremkina A, et al. Denosumab for management of severe hypercalcemia in primary hyperparathyroidism. Endocrine Connections 9: 1019-1027, No. 10, Oct 2020. Available 803519212 from: URL: http://doi.org/10.1530/EC-20-0380
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
